Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor

As part of an on-going lead optimisation effort, a cross screening exercise identified an aryl sulphonyl amide hit that was optimised to afford a highly potent series of ghrelin receptor agonists.

Graphical abstractAs part of an on-going lead optimisation effort, a cross screening exercise identified an aryl sulphonyl amide hit that was optimised to afford a highly potent series of ghrelin receptor agonists that displayed evidence of systemic exposure following oral administration.Figure optionsDownload full-size imageDownload as PowerPoint slide